Y Intercept Hong Kong Ltd Reduces Position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Y Intercept Hong Kong Ltd lowered its position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) by 47.8% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 12,699 shares of the specialty pharmaceutical company's stock after selling 11,622 shares during the quarter. Y Intercept Hong Kong Ltd's holdings in Jazz Pharmaceuticals were worth $1,415,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors have also bought and sold shares of the company. Itau Unibanco Holding S.A. bought a new stake in Jazz Pharmaceuticals in the second quarter valued at approximately $29,000. EverSource Wealth Advisors LLC lifted its position in Jazz Pharmaceuticals by 55.1% in the second quarter. EverSource Wealth Advisors LLC now owns 273 shares of the specialty pharmaceutical company's stock valued at $30,000 after purchasing an additional 97 shares during the last quarter. Gladius Capital Management LP bought a new stake in Jazz Pharmaceuticals in the second quarter valued at approximately $33,000. GAMMA Investing LLC lifted its position in Jazz Pharmaceuticals by 41.3% in the third quarter. GAMMA Investing LLC now owns 414 shares of the specialty pharmaceutical company's stock valued at $46,000 after purchasing an additional 121 shares during the last quarter. Finally, Venturi Wealth Management LLC lifted its position in Jazz Pharmaceuticals by 577.0% in the third quarter. Venturi Wealth Management LLC now owns 826 shares of the specialty pharmaceutical company's stock valued at $92,000 after purchasing an additional 704 shares during the last quarter. Hedge funds and other institutional investors own 89.14% of the company's stock.

Jazz Pharmaceuticals Stock Up 0.5 %

JAZZ stock traded up $0.57 during midday trading on Wednesday, hitting $120.72. The stock had a trading volume of 429,095 shares, compared to its average volume of 667,494. The firm has a market cap of $7.30 billion, a price-to-earnings ratio of 17.00, a price-to-earnings-growth ratio of 1.04 and a beta of 0.57. The business has a 50-day moving average of $116.81 and a two-hundred day moving average of $111.91. Jazz Pharmaceuticals plc has a 52-week low of $99.06 and a 52-week high of $134.17. The company has a debt-to-equity ratio of 1.46, a current ratio of 4.26 and a quick ratio of 3.74.

Insider Transactions at Jazz Pharmaceuticals

In other news, EVP Neena M. Patil sold 3,700 shares of the stock in a transaction on Friday, November 8th. The stock was sold at an average price of $123.41, for a total value of $456,617.00. Following the sale, the executive vice president now directly owns 33,048 shares of the company's stock, valued at approximately $4,078,453.68. This represents a 10.07 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Bruce C. Cozadd sold 2,000 shares of the stock in a transaction on Monday, December 2nd. The stock was sold at an average price of $121.17, for a total value of $242,340.00. Following the completion of the sale, the chief executive officer now directly owns 427,025 shares in the company, valued at approximately $51,742,619.25. This represents a 0.47 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 6,753 shares of company stock valued at $816,289. Insiders own 4.20% of the company's stock.

Analyst Ratings Changes

Several brokerages have weighed in on JAZZ. JPMorgan Chase & Co. boosted their price objective on Jazz Pharmaceuticals from $190.00 to $202.00 and gave the company an "overweight" rating in a research report on Monday, August 19th. Piper Sandler reiterated an "overweight" rating and issued a $163.00 price objective (down previously from $166.00) on shares of Jazz Pharmaceuticals in a research report on Thursday, November 21st. TD Cowen decreased their target price on Jazz Pharmaceuticals from $200.00 to $195.00 and set a "buy" rating for the company in a report on Thursday, November 7th. HC Wainwright restated a "buy" rating and set a $200.00 target price on shares of Jazz Pharmaceuticals in a report on Friday, November 22nd. Finally, Robert W. Baird upped their target price on Jazz Pharmaceuticals from $154.00 to $162.00 and gave the company an "outperform" rating in a report on Monday, November 18th. Three analysts have rated the stock with a hold rating, twelve have given a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat, Jazz Pharmaceuticals currently has an average rating of "Moderate Buy" and an average price target of $175.33.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.